News & Updates

Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.

Giving oral anticoagulants to patients with device-detected atrial fibrillation (AF) and multiple comorbidities does not necessarily help lower the rate of cardiovascular events, according to a subgroup analysis of the NOAH-AFNET 6 trial.

The use of diltiazem, especially at doses exceeding 120 mg/d, appears to contribute to a heightened risk of serious bleeding compared with metoprolol in patients with atrial fibrillation (AF) who are receiving oral anticoagulant therapy, according to a retrospective cohort study.

In the placebo-controlled ORBITA-COSMIC* trial, an implantable coronary sinus reducer (CSR) does not increase transmural myocardial perfusion, but it reduces the frequency of angina and improves quality of life (QoL) in patients with no further antianginal options.

Patients with ankylosing spondylitis who are exposed to higher doses of nonsteroidal anti-inflammatory drugs (NSAIDs) appear to have an elevated risk of cardiovascular disease (CVD), according to a study.

A multicomponent intervention to control elevated blood pressure (BP) levels at the primary care level, SingHypertension, represents good value for money for reducing hypertension-related morbidity and mortality in Singapore, according to a cost-effectiveness study.

Use of transcatheter aortic valve implantation (TAVI) does not increase the risks and contributes to a decrease in the rates of death or stroke at 1 year in patients with severe aortic stenosis when compared with surgical aortic-valve replacement (SAVR), suggests a study presented at ACC.24.

New drug applications approved by US FDA as of 1-15 April 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Using intravascular ultrasound (IVUS) to guide stent placement in patients with acute coronary syndrome (ACS) appears to reduce the 1-year risk of target vessel failure as compared with using angiography alone, according to the results of the IVUS-ACS study.